The success of the Covid-19 vaccine has led Pfizer and BioNTech to team up to develop a vaccine for shingles.
Pfizer and BioNTech are working together to make a vaccine.
Los Angeles Times.
If the vaccine is successful, it will be the first shot for preventing shingles, a painful disease that can occur in older adults when the virus that causes chickenpox reactivates after lying dormant in the body for years.
The vaccine will be tested in the second half of the 20th century.
The shot will combine the work of Pfizer and BioNTech, which are both involved in vaccine research.
Pfizer will make an upfront payment of $75 million and BioNTech will get an equity investment of $150 million, as well as milestone payments of up to $200 million and a share of profits from future sales, according to the companies.
Pfizer will receive an upfront payment for its work with BioNTech.
Continue watching after the ad Visit Advertiser website.
This is the third collaboration between BioNTech and Pfizer. The two began collaborating on a flu vaccine in the fall of 2018, and are well known for their Covid-19 shot.
The key background.
Pfizer and BioNTech said that they have the opportunity to develop an improved vaccine that could be more efficient to produce. Moderna is one of the vaccine makers that sees potential in the technology, which was proven during the Covid-19 pandemic after decades of research. MRNA vaccines introduce genetic material that instructs cells in the body to make a vaccine that works by introducing part of a disease-causing organism into the body.
Pfizer's chief scientific officer said that the agreement means the two companies are continuing on their journey of discovery together, by furthering the use of mRNA technology to tackle another health challenge ripe for scientific innovation.
A new generation of drugs is possible because of the success of the vaccine.
